Drug intelligence / Profile preview

GSK40974386

Development stage: Preclinical
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

GSK40974386 is an anti-LAG-3 antibody developed by AnaptysBio and licensed to GlaxoSmithKline (GSK) for development and commercialization in immuno-oncology. It functions as an immune checkpoint inhibitor, targeting the LAG-3 pathway to potentially enhance anti-tumor immune responses. The drug is part of a broader collaboration between AnaptysBio and GSK for therapeutic antibodies against various immune checkpoint receptors.

Targets

LAG3 (Lymphocyte activation Gene-3 protein)

Beyond the preview

Go deeper on GSK40974386.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK40974386.

Explore the full profile